Vaxart, Inc.
NASDAQ:VXRTBiotechnology
-$0.01 today
- Market cap
- $129.30M
- Beta
- 1.09
- P/E (TTM)
- 3.6
- EPS (TTM)
- $0.15
Volume 0.12M
Average 0.41M
VXRT Net Income
Bottom-line profit after all expenses, interest, and taxes.
Vaxart, Inc.NASDAQ: VXRT
Net Income · Q1 FY2026 · quarter ended Mar 2026
Net income turns positive
Q1 FY2026 net income was $5.18M, compared with -$15.59M a year earlier. Trailing-twelve-month net income was $37.1M.
Context
- Net income amounted to 6.9% of revenue in FY2025, down 226.4 pp from a year earlier.
- Net income increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether net income reaches the consensus estimate from 1 analysts of -$87.53M (-636.1%) for the fiscal year ending Dec 2026, a slowdown from the +124.4% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- $5.18M-90.6% QoQ
- Last fiscal yearDec 2025
- $16.33M+124.4% YoY
- LTMMar 2026
- $37.1M+163.8% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | +133.2% | -239.4% | -372.6 pp |
| 1 year | +124.4% | -636.1% | -760.5 pp |
| 3-year CAGR | — | — | — |
| 5-year CAGR | — | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Net Income history
USD · from the income statement
- Latest · FY2025
- 16.33M USD
- Year-over-year change
- +124.4%
| Period | Period end | Net Income | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 16.33M | +124.4% |
| FY2024 | 2024-12-31 | (66.95M) | +18.8% |
| FY2023 | 2023-12-31 | (82.47M) | +23.5% |
| FY2022 | 2022-12-31 | (107.76M) | -52.9% |
| FY2021 | 2021-12-31 | (70.47M) | — |
Net Income vs competitors
How VXRT compares with its peers on the latest reported figures
- VXRT's LTM Mar 2026 net income of $37.1M is the 2nd highest of the 10 companies compared; the peer median is -$78.34M.
- Its year-over-year change of +163.8% is the 2nd highest of 10, against a peer median of +5.5%.
- Net income amounts to 14.5% of revenue for VXRT, versus a peer median of 1777.2%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $127.77M | +410.4% | — | 193.1% | |
| LTM Mar 2026 | $37.1M | +163.8% | — | 14.5% | |
| LTM Mar 2026 | -$39.95M | -162.9% | — | — | |
| LTM Mar 2026 | -$58.88M | +22.2% | — | — | |
ACRVAcrivon Therapeutics, Inc. Common Stock | LTM Mar 2026 | -$77.27M | +7.7% | — | — |
| LTM Mar 2026 | -$78.34M | -28.7% | — | — | |
| LTM Mar 2026 | -$86.3M | -66.7% | — | 2193.7% | |
CBUSCibus, Inc. | LTM Mar 2026 | -$101.42M | +63.1% | — | 2366.3% |
| LTM Mar 2026 | -$104.29M | -8.2% | — | — | |
| LTM Mar 2026 | -$124.31M | +5.5% | — | 1360.6% | |
| Peer median (excluding VXRT) | -$78.34M | +5.5% | — | 1777.2% | |
Competitors are the stored peer set for VXRT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 892K | 107K | 7.38M | 28.7M | 237.26M |
| Cost of Revenue | 48.75M | 0 | 4.5M | 0 | 0 |
| Gross Profit | (47.86M) | 107K | 2.88M | 28.7M | 237.26M |
| Gross Margin | -5365.1% | 100.0% | 39.0% | 100.0% | 100.0% |
| Research & Development | 48.75M | 81.05M | 68.14M | 74.21M | 201.58M |
| Selling, General & Admin | 21.89M | 29.39M | 22.58M | 20.78M | 17.61M |
| Operating Expenses | 24.9M | 114.69M | 86.23M | 94.99M | 219.18M |
| Depreciation & Amortization | 2.43M | 5.81M | 8.62M | 8.85M | 8.58M |
| EBITDA | (66.45M) | (100.58M) | (72.13M) | (54.87M) | 28.21M |
| EBITDA Margin | -7449.7% | -94000.9% | -977.5% | -191.2% | 11.9% |
| Operating Income | (72.75M) | (114.59M) | (83.35M) | (66.29M) | 18.07M |
| Operating Margin | -8156.1% | -107090.7% | -1129.5% | -231.0% | 7.6% |
| Interest Income | 81K | 1.25M | 2.65M | 2.54M | 1.6M |
| Interest Expense | 1.48M | 1.31M | 1.45M | 2.97M | 2.82M |
| Other Income / Expenses | 2.39M | 6.9M | 1.14M | (395K) | (1.27M) |
| Income Before Tax | (70.36M) | (107.69M) | (82.2M) | (66.69M) | 16.8M |
| Pre-Tax Margin | -7888.2% | -100645.8% | -1114.0% | -232.4% | 7.1% |
| Income Tax Expense | 107K | 67K | 261K | 260K | 476K |
| Net Income | (70.47M) | (107.76M) | (82.47M) | (66.95M) | 16.33M |
| Net Margin | -7900.2% | -100708.4% | -1117.6% | -233.3% | 6.9% |
| EPS (Basic) | (0.14) | (0.22) | (0.17) | (0.14) | 0.07 |
| EPS (Diluted) | (0.14) | (0.22) | (0.17) | (0.14) | 0.07 |
| Weighted Avg Shares | 487.26M | 487.26M | 487.26M | 487.26M | 230.27M |
| Weighted Avg Shares (Diluted) | 487.26M | 487.26M | 487.26M | 487.26M | 230.35M |
Vaxart, Inc.
NASDAQ:VXRT
Intrinsic Alpha fair value
Locked
Current Price
$0.53
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.